At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.
Inventiva’s mid-stage win has revived hopes for PPAR agonists in the liver disease, although safety questions remain.
Five years after failing phase II in Nash, elafibranor fails phase III in Nash; a focus on liver cirrhosis beckons.
Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
Genfit's quiet delay means it will be five years since a Nash failure before investors find out whether pressing on into phase III was worth it.